Trials / Conditions / Whole Cell Pertussis

Whole Cell Pertussis

13 registered clinical trials studyying Whole Cell Pertussis.

Status	Trial	Sponsor	Phase
Completed	Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy To NCT01106092	GlaxoSmithKline	Phase 2
Completed	Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib NCT00473668	GlaxoSmithKline	Phase 3
Completed	Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTP NCT00332566	GlaxoSmithKline	Phase 3
Terminated	Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 M NCT00316680	GlaxoSmithKline	Phase 3
Completed	Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infan NCT00197275	GlaxoSmithKline	Phase 3
Completed	Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m NCT00136604	GlaxoSmithKline	Phase 3
Completed	Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children NCT00228917	GlaxoSmithKline	Phase 3
Completed	Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given i NCT00169442	GlaxoSmithKline	Phase 3
Completed	Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Bi NCT00317161	GlaxoSmithKline	Phase 3
Completed	Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B NCT00317187	GlaxoSmithKline	Phase 3
Completed	Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vacc NCT00290303	GlaxoSmithKline	Phase 3
Completed	Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis NCT00317135	GlaxoSmithKline	Phase 3
Completed	A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. NCT00317174	GlaxoSmithKline	Phase 2